I
InSphero
Perfecting 3D cell technology for more physiologically relevant in vitro insights
About InSphero
InSphero is a cutting-edge biotechnology startup that specializes in developing advanced 3D cell culture models and organ-on-a-chip technology. These innovative solutions are designed to mimic human tissue and organ functions, providing researchers with more accurate and reliable data for drug testing and disease research. The company primarily serves pharmaceutical and biotechnology companies, academic institutions, and research organizations focused on complex diseases such as diabetes, cancer, and liver diseases.
Read full description
Operating in the biomedical research market, InSphero offers a range of products and services that include 3D microtissue models, specially formulated media, and optimized assay protocols. Their technology allows for the creation of physiologically relevant models that can replicate human disease progression and tissue interactions more accurately than traditional 2D cell cultures. This leads to better predictive data for drug efficacy and safety, ultimately accelerating the drug development process.
InSphero's business model revolves around selling their 3D cell culture products and providing specialized testing services. They generate revenue by offering these products and services to their clients, who rely on InSphero's expertise to conduct high-quality, reproducible experiments. Additionally, the company offers expert support from experienced application scientists and the option to outsource testing to their services team, providing a comprehensive solution for their clients' research needs.
By focusing on innovation and quality, InSphero ensures that their microtissue models meet stringent standards, such as the EN ISO 9001 Quality System. This commitment to excellence has made them a trusted partner for leading pharmaceutical companies and research institutions worldwide.
At a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Schlieren, Switzerland
- Employees
- 81
- Open positions
- 1
- Dealroom signal
- 79.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Predictive Analytics, Biotechnology, Oncology, Microfluidics
- Technology
- Artificial Intelligence, 3D Technology, Big Data, Deep Tech, Computer Vision
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest May 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Sep 2024 | $0 | — | Breakthrough T1D | ↗ |
| LATE VC✓Equity / VC | Mar 2023 | $10M | $40M | Zeiss | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for InSphero is 9K monthly website visits, up 13.9% over the last three months. InSphero's team grew 2.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PhenoVista BiosciencesSan Diego, United StatesCombines physiologically-relevant 2D and 3D cell models and quantitative fluorescence imaging
→
DopplLausanne, SwitzerlandOrganoid models for preclinical drug development
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Venture Kick
Breakthrough T1D
Series A2 investors entered at this stage
Redalpine
ZKB - Zürcher Kantonalbank
Series B and later4 investors entered at this stage
- HAHP WILD HOLDING AG
OCCIDENT
Jürg Gysi
Zeiss
Other known investors7 additional known investors
ETH Zurich
Swissnex
University of Zürich
Beat Schillig
Technology fund
VentureLab
ZEISS Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InSphero on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InSphero’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.